Status:
RECRUITING
EtCO2 for Monitoring and Predicting Severity of DKA in Pediatric Emergency, Doha, Qatar.
Lead Sponsor:
Hamad Medical Corporation
Conditions:
Diabetes Mellitus
Eligibility:
All Genders
Up to 14 years
Brief Summary
Metabolic acidosis is one of the important and life-threatening pathophysiological changes in DKA and its monitoring is essential. It is known that the level of carbon dioxide (CO2) in the blood is co...
Detailed Description
The study will be conducted in pediatric emergency center, Hamad General Hospital, a recognized academic institution, in Doha, Qatar. The DKA was defined as: hyperglycemia (blood glucose \>11 mmol/L ...
Eligibility Criteria
Inclusion
- All children with already known or newly diagnosed diabetics, regardless weather has been enrolled in previous encounter or not.
Exclusion
- Older than 14 years of age
- Airway obstruction
- Chest infection
- Complex congenital heart disease
- Congestive heart failure
- Central or peripheral neurological disorders
- Hyper/hypothermia
- Severe pain
Key Trial Info
Start Date :
October 10 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2024
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT04121572
Start Date
October 10 2019
End Date
December 31 2024
Last Update
February 28 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hamad Medical Corporation
Doha, Qatar, 3050